Drug Profile
Research programme: diabetes/obesity therapy - Devgen
Alternative Names: Dev 0104Latest Information Update: 10 Jul 2008
Price :
$50
*
At a glance
- Originator Devgen
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Apr 2004 This programme is still in active development - (BioSquare-2004)
- 10 Jul 2001 Preclinical development for Diabetes and Obesity in Belgium (Unknown route)